Medtronic to Profile Extensive Safety and Clinical Data at Transcatheter Cardiovascular Therapeutics (TCT) Meeting.

Data Represents Most Comprehensive Assessment to Date of Endeavor([R]) Zotarolimus-Eluting Coronary Stent System

MINNEAPOLIS -- Medtronic, Inc. (NYSE:MDT), today announced a series of events to be held at next week's 19th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation, in Washington, D.C., that will include the most comprehensive assessment to date of Medtronic's Endeavor[R] zotarolimus-eluting coronary stent system around the world. Among the highlights are:

MAIN ARENA PLENARY SESSIONS

* ENDEAVOR IV: A randomized assessment of a zotarolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: 8-month angiographic and 12-month clinical results

Martin B. Leon, Monday, October 22 at 10:50 am ET

* AMETHYST: A prospective, randomized trial of a novel distal protection device during saphenous vein graft intervention

Dean J. Kereiakes, Monday, October 22 at 12:00 pm ET

* EXPORT: A prospective, randomized trial of thromboaspiration during primary angioplasty in acute myocardial infarction 

Bernard R. Chevalier, Tuesday, October 23 at 12:45 pm ET

* ENDEAVOR SAFETY: Adjudicated pooled meta-analysis of the early and late safety of a zotarolimus-eluting stent

Laura Mauri, Wednesday, October 24 at 12:00 pm ET

Each of these sessions will be followed by a critical appraisal of the corresponding trial.

ABSTRACTS

In addition to these plenary sessions, new data from a variety of Medtronic-sponsored studies will be released during TCT:

* Pooled analyses of data from more than 2,100 patients treated with the Endeavor drug-eluting stent in ENDEAVOR I - IV

* 12-month data for nearly 2,000 patients enrolled in ENDEAVOR Five, an 8,000-patient registry assessing real-world performance of the Endeavor drug-eluting stent

* 12-month data from ENDEAVOR Japan, a 99-patient study of the Endeavor drug-eluting stent in a Japanese population

* 12-month data from the RESOLUTE trial, a 130-patient study of the Endeavor Resolute drug-eluting stent

* Pre-clinical and biocompatibility data on BioLinx, the unique polymer blend for the Endeavor Resolute drug-eluting stent

ANALYST MEETING/WEBCAST AND MEDIA Q&A

Also during TCT, Medtronic will host an analyst meeting and Webcast on Monday, October 22 from 1-2 pm ET to provide an update on its CardioVascular business, including the latest clinical and market developments in the ENDEAVOR clinical program. The analyst meeting will be held at the Embassy Suites Convention Center, located at 900 10th Street NW, in Washington, D.C. Featured speakers include Scott Ward, president of Medtronic CardioVascular, and Sean Salmon, vice president and general manager of Medtronic's Coronary and Peripheral business. Live audio Webcast of the presentation will be available to all interested parties at Medtronic's Investor Relations Web site at http://investorrelations.medtronic.com. The analyst meeting will be followed by a media question-and-answer session with Ward and Salmon.

SCIENTIFIC SYMPOSIA

In addition, Medtronic is hosting a series of scientific symposia during TCT:

* A New Era in PCI / Monday, October 22 from 7 - 9:30 pm ET at the Renaissance Washington DC Hotel, Grand Ballroom: A discussion of the impact of DES safety concerns, the role of BMS and COURAGE data on the practice of PCI in the U.S. and Europe

* Practical Techniques for Treating Complex Coronary Artery Disease / Tuesday, October 23 from 7 - 8 am ET at the Washington Convention Center, Room 150B

* Practical Approaches to Treating Complex Vascular Diseases / Wednesday, October 24 from 7 - 8 am ET at the Washington Convention Center, Room 150B

* Acute and Chronic Care of the Patient with the Thrombus-Bearing Lesion / Thursday, October 25 from 7 - 8 am ET at the Washington Convention Center, Room 202A

"TCT provides an excellent scientific forum for clinicians to evaluate the cumulative data on the safety and efficacy of the Endeavor drug-eluting stent," Ward said. "Now that the FDA Circulatory System Devices Panel has unanimously voted to recommend approval of Endeavor in the United States, interventional cardiologists will be especially interested in learning about the most recent findings from the ENDEAVOR clinical program. We look forward to highlighting the improvements that a new class of drug-eluting stents can bring to physicians and patients."

Medtronic will occupy booth #3119 at the Washington Convention Center. The booth will feature stations on coronary stent systems, coronary crossing solutions, peripheral solutions, coronary aspiration and embolic protection systems, and endovascular solutions.

About Medtronic

Medtronic, Inc. (www.medtronic.com), headquartered in Minneapolis, is the global leader in medical technology - alleviating pain, restoring health, and extending life for millions of people around the world.

Caution: In the United States, the Endeavor Drug-Eluting Coronary Stent is an investigational device with an investigational drug (zotarolimus) and is exclusively for clinical investigation.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's Annual Report on Form 10-K for the year ended April 27, 2007. Actual results may differ materially from anticipated results.